Please assess the completion status of the following clinical trial:

Trial Title: Etoposide, Filgrastim, and Plerixafor in Improving Stem Cell Mobilization in Treating Patients With Non-Hodgkin Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Have biopsy-confirmed non-Hodgkin lymphoma, of any type~* Must be eligible for autologous transplantation according to institutional guidelines~* Eastern Cooperative Oncology Group performance status of 0 or 1~* Karnofsky performance status of 70 to 100~* Negative for human immunodeficiency virus (HIV)~* prior to the start of mobilization, subjects must have:~  * Absolute neutrophil count of \>= 1.2 x 10\^9/L~ * Platelet count of \>= 100 x 10\^9/L~ * Creatinine clearance \>= 30 mL/minute~* All patients must be able to comprehend and sign informed consent~* If childbearing potential must either agree to complete abstinence from heterosexual intercourse or effective means of contraception during stem cell mobilization and for at least 3 months following last plerixafor dose; female patients will undergo pregnancy test prior to stem cell mobilization therapy~Exclusion Criteria:~* Have had previous transplants and/or prior mobilization attempts~* Have evidence of progressive non-Hodgkin lymphoma~* Have evidence of bone marrow involvement of lymphoma at time of transplant staging~* Had evidence of active central nervous system (CNS) involvement~* Have had previous radiation of the pelvic area~* Have had prior radioimmunotherapy~* Have received experimental therapy within 2 weeks of enrollment~* Be currently enrolled in another investigational protocol~* Have prior history of other malignancies, excluding basal cell carcinoma or squamous cell carcinoma of the skin

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 78 Years
- Healthy Volunteers: f

Study Arms:
- Treatment (stem cell supermobilization) (Type: EXPERIMENTAL): Patients receive etoposide IV over 4 hours on day 0, filgrastim SC QD beginning day 1, and plerixafor SC 15-18 hours prior to apheresis. Patients unable to achieve target collection of \>= 8 x 10\^6 CD34+ cells/kg receive another dose of plerixafor followed by apheresis. Following the second apheresis, patients achieving =\< 2 x 10\^6 CD34+ cells/kg may continue filgrastim with plerixafor and continue collection according to the attending physician.

Based on this trial design, predict the completion outcome and termination type (if applicable).